What are the risks and benefits of non-admission prescribing for chronic disease management?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18310780
Cited by: 0

Abstract

Non-admission prescribing for chronic diseases can improve access and reduce costs but requires careful implementation to overcome technological and resource barriers, and to ensure quality care.

Fields of Study & Subjects

Primary Care and Health Outcomes Chronic Disease Management Strategies Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
20 January 2026